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Introduction
Complications related to the anesthetic process are
multifaceted and abundant. As a future nurse anesthesia
student, the underlying pathophysiology, diagnosis, and
treatment of anesthesia-related complications are of particular
interest. One such anesthesia-induced life-threatening
metabolic process involves the hypermetabolism of skeletal
muscle. This pharmacogenetic process, known as malignant
hyperthermia (MH), has a variable incidence rate ranging from
1:10,000 to 1: 250,000 anesthetic cases. However, the
prevalence of the genetic abnormalities may be as great as one
in 400 individuals (Rosenberg, Pollock, Schiemann, Bulger, &
Stowell, 2015, p. 1). “Malignant hyperthermia (MH) is a rare,
but life-threatening, autosomal-dominant inherited disorder that
may lead to metabolic crisis of skeletal muscle in susceptible
individuals following exposure to triggering agents, such as
volatile anesthetics or depolarizing muscle
relaxants” (Schneiderbanger, Johannsen, Roewer, & Schuster,
2014, p. 355).

Significance of Pathophysiology
According to Dirksen et al. (2013), the MH response spurs a
cascade of reactions, including increased sympathetic
activity, increased production of carbon dioxide, heat from
rapid use of adenosine triphosphate (ATP), increased
oxygen consumption, excess lactate production, and
cellular damage and destruction. The cellular membrane
disruption that occurs with MH has multiple consequences,
including potassium, phosphate, magnesium, and
myoglobin leakage into the extracellular fluid, causing a rise
in serum levels (Klingler et al., 2014). Complications related
to the progression of these cellular alterations include:
skeletal muscle damage, hyperthermia, renal failure,
cardiac arrest, and possible death (Dirksen et al., 2013).

Underlying Pathophysiology
The pathophysiologic process initiated by these pharmacologic
insults is characterized by a disruption in the regulation of calcium
within muscle cells. This buildup of intracellular calcium results in
the initiation of an immense hypermetabolic reaction stimulating
widespread muscle contraction (McCance & Heuther, 2014, p.
501). This buildup of intracellular calcium is a result of
“uncontrolled sarcoplasmic calcium release caused by mutations
in the ryanodine receptor subtype 1 (RYR1)” (Schuster,
Johannsen, Schneiderbanger, & Roewer, 2013). This gene
encodes an ion channel in the skeletal muscle cell through which
calcium flows. “In the presence of an abnormal RYR1 gene in
MH-susceptible individuals, a triggering agent such as halothane,
isoflurane, sevoflurane, desflurane, or enflurane, either alone or
in combination with the depolarizing muscle relaxant
succinylcholine, initiates uncontrolled calcium release. This sets
off the classic actin-myosin troponin interaction, shortening of
muscle fibers, and consequent muscle contraction. The
uncontrolled rise in intracellular calcium causes a sustained state
of muscle contraction, leading to the hypermetabolic MH
response” (Dirksen, Van Wicklin, Mashman, Neiderer, & Merritt,
2013, p. 331).

Signs & Symptoms
“Almost all patients who are MH susceptible have no phenotypic
changes without anesthesia, it is impossible to diagnose susceptibility
without either exposure to the “trigger” anesthetics or by specific
diagnostic testing” (Rosenberg et al., 2015, p. 2). This reinforces the
importance of educating anesthesia providers, and nurses alike on
the signs and symptoms of this pharmacogenetic process.
“Characteristic clinical signs of MH during general anesthesia include
hypoxemia, hypercapnia, tachycardia, muscular rigidity, acidosis,
hyperkalemia and hyperthermia” (Schuster et al., 2013, p. 1). The
“malignant hyperthermia clinical grading scale” bases the level of
severity of MH crisis on six indicators: rigidity, muscle breakdown,
respiratory acidosis, temperature increase, cardiac involvement, and
other indicators of metabolic derangement not part of a single
process (Heytens, Forget, Scholtes, & Veyckemans, 2015, p. 506).
“An increase in end-tidal carbon dioxide despite increased minute
ventilation provides an early diagnostic clue” (Rosenberg et al., 2015,
p. 1).

“Many clinicians are unprepared to manage an MH crisis in
the perioperative setting because it requires the use of lowfrequency, high-risk skills and procedures” (Cain, Riess,
Gettrust, & Novalija, 2014, p. 301). Nurses should
familiarize themselves with the signs and symptoms of MH,
and be ready to implement their institutions treatment plan
in the event of this complication. The widely accepted
treatment for MH is to first remove the triggering anesthetic
agent when an impeding MH crisis is expected (Cain et al.,
2014, p. 302). Dantrolene is a commonly used medication
in the treatment of MH, which directly interferes with
skeletal muscle contractions by decreasing the level of
calcium in the muscle cells. Dantrolene does not block
neuromuscular transmission, but rather potentiates
nondepolarizing neuromuscular blockade (Brandom, &
Riazi, 2015, p. 17). Active cooling in patients suffering from
a MH crisis is paramount, with ice being the most widely
used surface coolant. The patient’s core temperature
should be lower than 39 degrees Celsius (Cain et al., 2014,
p. 302).

Conclusion
MH is a rare, but life-threatening complication. Many
clinicians may find themselves unprepared to manage a
patient in a MH crisis. Hospitals should encourage their
anesthesia providers to take part in routine clinical
simulations to be better prepared to react promptly and
efficiently. The research surrounding MH is ongoing, and
complicated due to the rarity of these events. The
cessation of previously known triggering agents, such as
halothane, has substantially decreased the incidence of
MH in the last 20 years (Heytens, Forget, Scholtes, &
Veyckemans, 2015, p. 508). However, the need for
research and development of treatment plans for this
complication is vital to the continued decline in MH crisis
events.
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